Bone Biologics Corp. (NASDAQ:BBLG) Shares Shorted: Short Interest Down 54.0% in October

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 22,777 shares, a drop of 54.0% from the September 30th total of 49,512 shares. Based on an average daily volume of 41,660 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.9% of the shares of the company are short sold.

Bone Biologics Stock Performance

Shares of NASDAQ BBLG traded down $0.01 during mid-day trading on Friday, reaching $0.38. The company’s stock had a trading volume of 14,407 shares, compared to its average volume of 39,781. The stock has a market capitalization of $1.29 million, a P/E ratio of -0.33 and a beta of 0.90. The stock has a 50-day moving average of $0.49 and a two-hundred day moving average of $1.06. Bone Biologics has a 1-year low of $0.36 and a 1-year high of $2.39.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Monday, October 26th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. Analysts predict that Bone Biologics will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research report on Thursday, October 22nd. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Bone Biologics

Bone Biologics Corporation is a biotechnology and medical device company focused on developing regenerative products for bone repair and spinal fusion. Its technology platform is based on NELL-1, a recombinant human protein designed to stimulate bone growth and support the formation of new bone.

The company’s lead development programs combine NELL-1 with resorbable bone-graft scaffolds for use in orthopedic and spinal procedures. These products are intended to provide surgeons with alternatives or supplements to conventional bone-grafting approaches, with an initial emphasis on spinal fusion applications.

Bone Biologics has conducted its research and development activities in collaboration with academic and medical institutions, including researchers associated with the University of California, Los Angeles.